Sotatercept-csrk (Winrevair; Merck Sharp & Dohme) added on top of standard therapies improves outcomes in patients who are less than a year out from a diagnosis of pulmonary arterial hypertension (PAH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback